EXPLORE!

Telmisartan Outperforms Cilnidipine in Hypertension Management

  496 Views

#Diabetes and Endocrinology  #Family Medicine  #Internal Medicine 

Emedinexus    26 August 2025

Telmisartan, part of the angiotensin II receptor blocker (ARB) group with a long half-life and high bioavailability, and cilnidipine, a calcium channel blocker with dual action, were compared for their effects on ambulatory blood pressure (BP) in newly diagnosed stage-I hypertension patients.


In a prospective, randomized, open-label trial, 40 patients received either telmisartan 40 mg or cilnidipine 10 mg once daily for 56 days. Ambulatory BP monitoring was conducted before and after treatment to assess outcomes.


Both drugs were effective and well tolerated, but telmisartan showed broader and more significant reductions across all BP endpoints, whereas cilnidipine showed improvements only in 24-hour systolic BP (SBP), daytime SBP, nighttime SBP, and manual systolic and diastolic pressures.


The findings suggest that telmisartan offers 24-hour blood pressure control, with superior effects over cilnidipin, especially in the 18–24 hours after the dose interval, making it a more effective choice for managing mild to moderate hypertension.


Reference:


1.     Sawant R, Suryawanshi S, Jadhav M, Barkate H, Bhushan S, Rane T. A Prospective, Randomized Open-Label Study for Assessment of Antihypertensive Effect of Telmisartan Versus Cilnidipine Using Ambulatory Blood Pressure Monitoring (START ABPM Study). Cardiology Research. 2023 May 26;14(3):211.
https://pubmed.ncbi.nlm.nih.gov/37304922/

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.